Eosinophilic Cells as a Distinct Morphological Feature in <i>BRAF<sup>V600E</sup></i>-Mutated Ovarian Serous Borderline Tumors
<b>Background/Objectives</b>: According to recent reports, the <i>BRAF<sup>V600E</sup></i> mutation in serous borderline tumors (SBTs) plays a protective role against progression to low-grade serous carcinoma through oncogene-induced senescence. One consequence of...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/15/12/1479 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <b>Background/Objectives</b>: According to recent reports, the <i>BRAF<sup>V600E</sup></i> mutation in serous borderline tumors (SBTs) plays a protective role against progression to low-grade serous carcinoma through oncogene-induced senescence. One consequence of this is the appearance of eosinophilic cells (ECs). The aim of the current study was to determine the interobserver reproducibility of ECs and their predictive significance for the detection of the <i>BRAF<sup>V600E</sup></i> mutation in SBTs. <b>Methods</b>: The study was conducted using 63 cases of ovarian SBTs. Three gynecological pathologists, blinded to each tumor’s mutation status, assessed the presence of ECs. Immunohistochemical staining with p16 and Ki-67 was performed to validate ECs. Mutational analysis was carried out using targeted NGS. <b>Results</b>: Genetic analysis revealed 30 <i>BRAF</i>-mutated, 1 <i>NRAS</i>-mutated, and 9 <i>KRAS</i>-mutated SBTs. ECs were identified by the majority of pathologists (two or three) in 78% of the <i>BRAF<sup>V600E</sup></i>-mutated and 11% of the wild-type tumors with other mutations (<i>p</i> < 0.0001). The interobserver reproducibility of the presence of ECs was substantial (κ = 0.66). ECs validated with p16/Ki-67 were identified in 92.6% of the <i>BRAF<sup>V600E</sup></i>-mutated and in 13.8% of the wild-type tumors with other mutations (<i>p</i> < 0.0001). For the ECs identified by the majority of pathologists, the sensitivity and specificity when predicting the <i>BRAF<sup>V600E</sup></i> mutation were 77.8% and 88.9%, respectively. For the ECs validated with p16/Ki-67, the sensitivity and specificity when predicting the <i>BRAF<sup>V600E</sup></i> mutation were 95.3% and 90.5%, respectively. <b>Conclusions</b>: Overall, these results suggest that ECs in SBTs have potential association with the <i>BRAF<sup>V600E</sup></i> mutation. |
|---|---|
| ISSN: | 2075-4418 |